Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620503 · ClinicalTrials.gov registry record · Phase 1
Proellex® Pharmacokinetic Bridging Study II
A Phase 1 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00620503 is a Phase 1 study that has completed, run by Repros Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT00620503, a Phase 1 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
An open-label, randomized, single-center, outpatient, unblinded, single-dose, three-way crossover study of the safety and PK properties of Proellex® in women ages 18 - 34 years.
Interventions
- DRUG Proellex 25 mg formulation A
- DRUG Proellex 25 mg formulation B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-02-29 |
| Est. Completion | 2008-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620503
The ClinicalTrials.gov registry entry for NCT00620503 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Proellex 25 mg formulation A is the first listed.
NCT00620503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00620503 about?
NCT00620503 is a clinical study titled "Proellex® Pharmacokinetic Bridging Study II". An open-label, randomized, single-center, outpatient, unblinded, single-dose, three-way crossover study of the safety and PK properties of Proellex® in women ages 18 - 34 years.
What is the current status of trial NCT00620503?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-02-29. Estimated completion is 2008-04-30.
What interventions are being tested in trial NCT00620503?
The interventions under investigation include: Proellex 25 mg formulation A (DRUG), Proellex 25 mg formulation B (DRUG).
Who is sponsoring clinical trial NCT00620503?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.